Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Acerta Pharma BV
With
Merck Sharp & Dohme LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men and women ≥ 18 years of age
Histologically or cytologically confirmed urothelial carcinoma of the bladder or mixed histology bladder cancer
Metastatic bladder cancer with disease progression on or after platinum-based chemotherapy
Any primary site of urothelial carcinoma including upper tract, renal pelvis, bladder, and ureters
Prior therapy with ≥ 1 systemic chemotherapy regimens for urothelial carcinoma
Presence of radiographically measurable disease (defined as the presence of ≥ 1 lesion that measures ≥ 10 mm \[≥ 15 mm for lymph nodes\]
ECOG performance status of 0 or 1
You may not be if
Prior malignancy (other than bladder cancer), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 2 years of which will not limit survival to \< 2 years.
Known central nervous system metastases and/or carcinomatous meningitis
Malabsorption syndrome, disease significantly affecting gastrointestinal function
Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening
Clareo Health | Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer
